Indivior Pharmaceuticals Inc. (INDV)
NASDAQ: INDV · Pharmaceutical Preparations · Rockville, MD
Our rating: Cautious
Cautious reaffirmed at $35.37, moderate conviction, October 30, 2026.
Breaks if: The Cautious call would be wrong if free cash flow turns positive on a trailing-twelve-month basis in two consecutive quarterly reports by mid-2027 and the gap between net income and FCF narrows below $50M — signaling the cash drag has resolved and earnings quality has improved. From a price standpoint, a move above $42.44 (roughly 20% from the current $35.37) within six months, in the absence of any deterioration in the underlying reported figures, would also challenge the view.
Key figures
| Market value | $4.3B |
|---|---|
| Revenue, last 12 months | $1.4B |
| Net income, last 12 months | $450M |
| Free cash flow, last 12 months | $31M |
| Price to earnings | 9.5× |
| Free cash flow yield | 0.7% |
| Dividend yield | 0.0% |
| Operating margin | 40.6% |
| Return on equity | n/a |
| Beta to the S&P 500 | 0.65 |
| Volatility, annualized | 52.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $356M | 13.4% | $1.12 | $83M |
| June 30, 2026 | $343M | 13.6% | $0.98 | $222M |
| March 31, 2026 | $317M | 19.2% | $0.69 | −$29M |
| December 31, 2025 | $358M | 19.7% | $0.79 | −$245M |
| September 30, 2025 | $314M | 2.3% | $0.33 | −$59M |
| June 30, 2025 | $302M | 1.0% | $0.14 | $141M |
| March 31, 2025 | $266M | −6.3% | $0.38 | $70M |
| December 31, 2024 | $299M | n/a | $0.16 | −$33M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.42B: Claude 28%, Gemini 88%, Mistral 40%
- Diluted earnings per share are at least $0.79: Claude 55%, Gemini 93%, Mistral 75%
- Free cash flow for the quarter is above zero: Claude 65%, Gemini 65%, Mistral 60%
13 ledger entries and 18 corporate events on record. Share price as of November 2, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.